NHS Framework Agreement for Branded Medicines - Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025

NHS England

This public procurement record has 2 releases in its history.

Award

29 Jul 2025 at 15:34

Tender

17 Feb 2025 at 09:56

Summary of the contracting process

NHS England has finalised a Framework Agreement titled "NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab" for pharmaceutical products. This procurement process, classified under CPV 33600000, is primarily concerned with goods for the healthcare industry and covers regions including London, North of England, and Midlands & East. The tender was executed under an open procurement method, and the agreement period extends from 01 September 2025 to 31 August 2027 for Lot 1, and 31 August 2026 for Lot 2. NHS England acted as the central purchasing body, and key framework suppliers were awarded contracts on 1 July 2025.

This procurement represents a significant opportunity for suppliers in the pharmaceutical industry to participate in a comprehensive supply chain managed by a major public health body. It allows manufacturers of branded medicines to collaborate with NHS England, ensuring a substantial presence in public healthcare procurement. Large-scale suppliers, as well as SMEs, could particularly benefit from the strategic position and steady demand this framework offers, with options to extend contracts providing further long-term growth prospects.

How relevant is this notice?

Notice Information

Notice Title

NHS Framework Agreement for Branded Medicines - Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025

Notice Description

NHS Framework Agreement for Branded Medicines - Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025<br/>CM/PHR/24/5680/01 - Tranche B for North of England and Midlands & East. Period of Framework Agreement: 01 September 2025 to 31 August 2027 <br/>CM/PHR/24/5680/02 - Eculizumab and Ravulizumab for London & SOFE. Period of Framework Agreement: 01 September 2025 to 31 August 2026

Lot Information

Lot 1 - CM/PHR/24/5680/01 - Tranche B for North of England and Midlands & East

Tranche B for North of England and Midlands & East. Period of Framework Agreement: 01 September 2025 to 31 August 2027. Additional information: Price is not the only award criterion and all criteria are stated in the procurement documents.

Options: With an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.

Lot 2 - CM/PHR/24/5680/02 - Eculizumab and Ravulizumab for London & SOFE

Eculizumab and Ravulizumab for London & SOFE. Additional information: Price is not the only award criterion and all criteria are stated in the procurement documents.

Options: With an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months.

Notice Details

Publication & Lifecycle

Open Contracting ID
ocds-h6vhtk-04e273
Publication Source
Find A Tender Service
Latest Notice
https://www.find-tender.service.gov.uk/Notice/043951-2025
Current Stage
Award
All Stages
Tender, Award

Procurement Classification

Notice Type
Award Notice
Procurement Type
Framework
Procurement Category
Goods
Procurement Method
Open
Procurement Method Details
Open procedure
Tender Suitability
Not specified
Awardee Scale
Large, SME

Common Procurement Vocabulary (CPV)

CPV Divisions

33 - Medical equipments, pharmaceuticals and personal care products


CPV Codes

33600000 - Pharmaceutical products

Notice Value(s)

Tender Value
£4,108,145,000 £1B-£10B
Lots Value
£2,874,717,000 £1B-£10B
Awards Value
Not specified
Contracts Value
£1

Notice Dates

Publication Date
29 Jul 20251 years ago
Submission Deadline
7 Apr 2025Expired
Future Notice Date
Not specified
Award Date
Not specified
Contract Period
1 Sep 2025 - 31 Aug 2027 1-2 years
Recurrence
Not specified

Notice Status

Tender Status
Complete
Lots Status
Cancelled
Awards Status
Active
Contracts Status
Active

Buyer & Supplier

Contracting Authority (Buyer)

Main Buyer
NHS England
Contact Name
Available with D3 Tenders Premium →
Contact Email
Available with D3 Tenders Premium →
Contact Phone
Available with D3 Tenders Premium →

Buyer Location

Locality
LONDON
Postcode
SE1 8UG
Postcode Area
South East London
Country
England

Major Region (ITL 1)
TLI London
Basic Region (ITL 2)
TLI4 Inner London - East
Small Region (ITL 3)
TLI45 Lambeth
Delivery Location
Not specified

Local Authority
Lambeth
Electoral Ward
Waterloo & South Bank
Westminster Constituency
Vauxhall and Camberwell Green

Supplier Information

Number of Suppliers
21
Supplier Names

Biogen

Amgen Ltd

Sobi (Swedish Orphan Biovitrum Ltd)

Zentiva Pharma UK Ltd

Fresenius Kabi Limited

Sandoz Ltd

Thornton and Ross Ltd

Roche Products Ltd

Accord-UK Ltd

GlaxoSmithKline UK Limited

Samsung Bioepis UK Ltd

Pfizer Ltd

Janssen-Cilag Ltd

Celltrion Healthcare United Kingdom Limited

Abbvie Ltd

Takeda UK Ltd

Organon Pharmaceuticals UK Ltd

Alexion Pharmaceuticals

Orifarm UK

CuraTeQ Biologics s.r.o.

Dr.Reddy's Laboratories (UK) Limited

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

JSON Markdown

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.

Loading OCDS record...